Natco Pharma introduces anti-blood clot tablet in India
Natco Pharma introduces anti-blood clot tablet Rivaroxaban under brand RPIGAT in India
Natco Pharma today announced the launch of the Rivaroxaban molecule, under the brand RPIGAT. Rivaroxaban is an anticoagulant medication, which is used to treat as well as prevent blood clots.
The company had previously launched DABIGAT (Dabigatran) and APIGAT (Apixaban). The latest Rivaroxaban novel oral anti-coagulant (NOAC) is in line with the company's mission of affordable medicines accessible to all.
The stock of Natco Pharma has recovered by 133.46 per cent from its sharp decline of March 2020.
The company reported a net profit of Rs 203.9 crore in Q2FY21, an increase of 73.23 per cent. It had reported a profit of Rs 117.7 crore in Q2FY20. The company reported a total income of Rs 827.9 crore for Q2FY21, an increase of 59.55 per cent as against the total income of Rs 518.9 crore for Q2FY20.
According to BSE data, the stock traded at a P/E multiple of 43.02 and a price-to-book ratio of 4.28. The stock has a 52-week high and a 52-week low of Rs 995.05 per share and Rs 450 per share, respectively.
Natco Pharma is engaged in developing, manufacturing & marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).
On Thursday, the share price of the company closed at Rs 943.70, down by 0.63 per cent on BSE.